Genmab
GMAB
Market cap $13.2B

21.15 USD

+0.36

1.73%

At close Apr 30, 4:00 PM EDT

After hours

21.15

+0.00

0.00%

1 day

1.73%

5 days

3.93%

1 month

8.02%

3 months

6.76%

6 months

-6.29%

Year to date

0.71%

1 year

-23.62%

5 years

-13.07%

10 years

16.59%

About: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Employees: 2,682

Healthcare Biotechnology

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

294% more call options, than puts

Call options by funds: $3.44M | Put options by funds: $872K

19% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 42

12.82% more ownership

Funds ownership: 79.01% [Q3] → 91.83% (+12.82%) [Q4]

2% more funds holding

Funds holding: 222 [Q3] → 226 (+4) [Q4]

1% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 74

1% less capital invested

Capital invested by funds: $1.28B [Q3] → $1.27B (-$11.7M) [Q4]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$27

28%

upside

Avg. target

$36

72%

upside

High target

$45

113%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target	75%upside $37	Buy Reiterated	9 Apr 2025
Truist Securities Asthika Goonewardene 30% 1-year accuracy 7 / 23 met price target	113%upside $45	Buy Maintained	11 Mar 2025
Leerink Partners Jonathan Chang 50% 1-year accuracy 1 / 2 met price target	28%upside $27	Outperform Upgraded	13 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about GMAB published over the past 30 days

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions in Connection with Share Buy-back Program

Zacks Investment Research

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Should Value Investors Buy Genmab (GMAB) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Genmab (GMAB) Stock?

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab's strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and strategic acquisitions.

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 12, 2025, it was decided to reduce the Company's share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company's holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority.

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

See News Rankings

Charts implemented using Lightweight Charts™